L3VLUP
ProSign in

AORT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AORTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AORT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterAORTVRTX
Q3 20201 holders, $8.9m31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 20211 holders, $919k30 holders, $12.7bn
Q3 20211 holders, $531k35 holders, $10.1bn
Q4 20211 holders, $722k28 holders, $12.4bn
Q1 20221 holders, $1.8m23 holders, $16.1bn
Q2 20221 holders, $2.3m25 holders, $18.1bn
Q3 20221 holders, $1.9m22 holders, $18.4bn
Q4 20221 holders, $1.7m28 holders, $18.4bn
Q1 20231 holders, $3.1m26 holders, $21.4bn
Q2 20231 holders, $6.6m27 holders, $24.7bn
Q3 20231 holders, $8.0m33 holders, $24.3bn
Q4 20231 holders, $9.4m32 holders, $28.6bn
Q1 20241 holders, $12m31 holders, $29.8bn
Q2 20242 holders, $25m29 holders, $33.4bn
Q3 20241 holders, $17m27 holders, $33.5bn
Q4 20241 holders, $17m26 holders, $28.5bn
Q1 20251 holders, $11m21 holders, $35.4bn
Q2 20251 holders, $13m21 holders, $32.3bn
Q3 20251 holders, $14m22 holders, $25.9bn
Q4 20252 holders, $15m26 holders, $31.8bn
Q1 20261 holders, $11m25 holders, $31.8bn
Q2 20261 holders, $7.8m26 holders, $34.6bn
AORT

Artivion Inc

Holders
2
Reported value
$25m
Buyers
2
Sellers
0

Breadth +2 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only AORT (2)

ExodusPoint Capital Management LP, First Eagle Investment Management LLC

Only VRTX (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →